MOTS-c Research: Mitochondrial Signaling, Metabolic Evidence, and FDA Status

MOTS-c is a 16-amino-acid mitochondria-derived peptide encoded within a short open reading frame of mitochondrial 12S ribosomal RNA. It was reported in 2015 as part of a growing class of mitochondrial-derived peptides that may carry stress and metabolic signals between mitochondria and the rest of the cell. [2]

Most evidence for administered synthetic MOTS-c comes from cells and animals. FDA's 2026 review reported that it did not identify clinical studies or human exposure data involving administered MOTS-c. [1] A newly registered clinical study may begin to address that gap, but it has no posted results as of this article's publication. [5]

What Is MOTS-c?

MOTS-c stands for mitochondrial open reading frame of the 12S rRNA type-c. Unlike peptides encoded by conventional nuclear genes, its sequence is derived from mitochondrial genetic material. The peptide has been detected endogenously in human and rodent circulation, although measuring small peptides reliably presents analytical challenges.

The naturally occurring peptide and a synthetic bulk drug substance are related but not interchangeable concepts. Studies that measure circulating MOTS-c do not automatically establish what happens when a manufactured form is administered. Identity, impurities, aggregation, formulation, and route are additional variables.

FDA separately evaluated MOTS-c free base and MOTS-c acetate for the July 2026 PCAC meeting. [1]

Proposed Mechanisms

AMPK and metabolic stress signaling

The original research connected MOTS-c with metabolic homeostasis and AMP-activated protein kinase (AMPK), a central sensor of cellular energy status. In cells and mice, investigators reported changes involving folate-cycle and purine metabolism, skeletal-muscle glucose handling, and insulin sensitivity. [2]

AMPK activation is not unique to MOTS-c, and pathway activation alone does not establish a clinical effect. It identifies a plausible biological route that must be connected to exposure, target engagement, dose-response, and meaningful outcomes.

Nuclear translocation and gene expression

Subsequent research has examined whether MOTS-c can move to the nucleus during metabolic stress and influence nuclear gene expression. This is an example of proposed mitochondrial-to-nuclear communication. The molecular targets and full receptor biology remain incompletely defined.

Exercise and muscle homeostasis

Animal and human observational work has explored relationships among exercise, circulating MOTS-c, age, and muscle metabolism. A 2021 study reported exercise-associated changes and administered the peptide to mice, with findings related to physical performance and age-dependent decline. [4] Observing a peptide change after exercise does not show that injecting synthetic peptide reproduces exercise or its health effects.

Animal and Cell Research

The best-known 2015 study reported that synthetic MOTS-c altered metabolic outcomes in mouse models, including diet-related obesity and insulin resistance. [2] Other animal and cell studies have examined:

Glucose uptake and skeletal-muscle metabolism
Plasma metabolites and insulin sensitivity [3]
Adipose thermogenesis
Bone-cell differentiation and osteolysis models
Vascular calcification
Age-associated physical decline [4]

FDA noted that these studies used in vitro and rodent models, often did not clearly distinguish free-base from salt forms, and did not establish clinical relevance. The agency also identified incomplete dose-response information and uncertainty about molecular targets. [1]

Human Research

There are two different categories of “human evidence” that should not be confused.

Endogenous measurement studies

Researchers have measured naturally occurring MOTS-c or MOTS-c-associated genetic variation in human samples and examined relationships with age, exercise, or metabolic traits. These studies can support biological relevance, but they do not test the safety or effectiveness of an administered product.

Interventional studies

FDA reported no identified clinical studies or human exposure data for administered MOTS-c in its briefing review. [1] ClinicalTrials.gov now lists NCT07505745, a study designed to evaluate MOTS-c in adults with early metabolic dysfunction. [5] Registration shows that a study is planned or underway; it is not evidence of a positive result. The registry should be checked for recruitment status, protocol changes, completion, and posted results.

Safety and Side Effects

MOTS-c does not have a clinically established side-effect profile. FDA reported no human exposure data by any route in the evidence it reviewed and concluded that potential human safety risks are unknown. [1]

Relevant uncertainties include:

Immune responses to an administered peptide
Aggregation and peptide-related impurities
Product identity and consistency
Off-target metabolic effects
Organ exposure and pharmacokinetics
Long-term or repeated-use effects

The fact that an endogenous peptide circulates in the body does not establish the safety of an exogenous manufactured product. Concentration, timing, route, chemical form, and product quality can all change biological effects.

MOTS-c is also relevant to sports governance. FDA's review notes its appearance in anti-doping resources. Athletes should evaluate current rules through the applicable governing body rather than infer permissibility from research status.

FDA and Compounding Status

MOTS-c is not an FDA-approved drug. FDA evaluated MOTS-c free base and MOTS-c acetate for potential placement on the 503A Bulks List, focusing on proposed uses involving obesity and osteoporosis.

FDA staff concluded that both forms were not well characterized, historical compounding use was unclear, human effectiveness and safety data were unavailable, and the overall balance weighed against listing. FDA proposed that neither form be added. [1]

PCAC is scheduled to discuss the proposal on July 23, 2026. That discussion is not a drug-approval review and will not, by itself, be FDA's final determination. The FDA PCAC peptide review hub will track the outcome.

Evidence Assessment

Evidence area	Current assessment
Biological origin	Endogenous mitochondrial-derived peptide identified
Mechanistic evidence	Multiple metabolic pathways proposed
Animal evidence	Substantial relative to human evidence
Human observational evidence	Endogenous levels and associations studied
Human administration evidence	None identified by FDA; a trial is registered
Long-term safety	Unknown
FDA approval	Not approved

Frequently Asked Questions

Is MOTS-c naturally produced by humans?

Research indicates that MOTS-c is encoded by mitochondrial genetic material and can be detected in human tissues or circulation. That does not establish the safety or effectiveness of administering a synthetic product.

Is MOTS-c an exercise mimetic?

Some research links MOTS-c with exercise signaling and reports effects in mice. Calling it an “exercise mimetic” overstates what has been demonstrated in humans.

Has MOTS-c been tested in people?

FDA reported no identified human administration studies in its 2026 briefing. A clinical study is now registered, but no results were posted when this article was published.

Is MOTS-c FDA approved?

No. The July 2026 review concerns the 503A Bulks List, not approval of MOTS-c as a drug.

How does MOTS-c compare with GLP-1 drugs?

They are different research categories. Approved GLP-1-based medicines act through defined incretin receptors and have extensive human trial programs. MOTS-c has a mitochondrial signaling hypothesis supported mainly by preclinical evidence. See GLP-1 receptor agonist research for that evidence base.